1. Home
  2. ZEPP vs ACRV Comparison

ZEPP vs ACRV Comparison

Compare ZEPP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zepp Health Corporation

ZEPP

Zepp Health Corporation

HOLD

Current Price

$4.89

Market Cap

77.7M

Sector

Technology

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.99

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZEPP
ACRV
Founded
2013
2018
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.7M
74.0M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
ZEPP
ACRV
Price
$4.89
$1.99
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
55.3K
333.4K
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$778.34
N/A
Revenue Next Year
N/A
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.85
$1.27
52 Week High
$61.50
$3.56

Technical Indicators

Market Signals
Indicator
ZEPP
ACRV
Relative Strength Index (RSI) 44.97 51.43
Support Level $4.08 $1.38
Resistance Level $5.65 $2.20
Average True Range (ATR) 0.38 0.12
MACD -0.01 -0.03
Stochastic Oscillator 53.28 18.57

Price Performance

Historical Comparison
ZEPP
ACRV

About ZEPP Zepp Health Corporation

Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands. Geographically, the group generates revenue from Asia-Pacific, Europe, North America and others.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: